Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 10/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30199628 | 0.86 | POLB (0.56) | TBXA2RSMN1; SMN2POLBHPGDL3MBTL1 | |
| SCHEMBL23833774 | 0.86 | POLB (0.56) | TBXA2RSMN1; SMN2POLBHPGDL3MBTL1 | |
| SCHEMBL25759494 | 0.81 | SLC22A12 (0.46) | SLC22A12POLBL3MBTL1 | |
| SCHEMBL2646997 | 0.78 | ALDH1A1 (0.42) | TBXA2RSMN1; SMN2TDP1HSD11B1L3MBTL1 | |
| SCHEMBL23833770 | 0.78 | AKR1C3 (0.41) | TBXA2RSMN1; SMN2TDP1HSD11B1 | |
| SCHEMBL7686888 | 0.74 | HSD17B10 (0.55) | SMN1; SMN2HPGD | |
| SCHEMBL25754683 | 0.72 | POLB (0.57) | TBXA2RSMN1; SMN2POLBTDP1HPGD | |
| SCHEMBL25754734 | 0.71 | POLB (0.55) | TBXA2RSMN1; SMN2NHERF1MCL1POLB | |
| SCHEMBL23833706 | 0.70 | NHERF1 (0.49) | TBXA2RSMN1; SMN2NHERF1MCL1TDP1 | |
| SCHEMBL23832708 | 0.70 | SMN1; SMN2 (0.54) | TBXA2RSMN1; SMN2POLBHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | TBXA2R 3207/4885SLC22A12 3263/4885SMN1; SMN2 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.